Cardiol Therapeutics Inc Class A (CRDL) Stock Analysis

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $1.07
• Market Cap: $112.24M
• EPS: $-0.30
• 52-Week High: $1.59
• 52-Week Low: $0.77

About Cardiol Therapeutics Inc Class A

Cardiol Therapeutics Inc. (CRDL) is a clinical-stage biotechnology company headquartered in Oakville, Canada, focusing on the development of innovative anti-inflammatory therapies for cardiovascular diseases (CVD). With a strong pipeline supported by advanced research and development efforts, the company is committed to addressing pressing unmet medical needs in CVD treatment. By harnessing leading-edge science and expertise in inflammation, Cardiol Therapeutics aims to deliver novel therapeu...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Cardiol Therapeutics Inc Class A and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CRDL pay dividends?

Cardiol Therapeutics Inc Class A (CRDL) does not currently pay a regular dividend.

What is CRDL's market cap?

Cardiol Therapeutics Inc Class A (CRDL) has a market capitalization of $112.24M with a current stock price of $1.07.